Literature DB >> 15866057

Prevalence of antiphospholipid antibodies is not different in Chilean diabetic patients and normal individuals.

Iván G Palomo1, Verónica E Mujica, Marcelo L Alarcón, Jaime G Pereira, Marcela R Vásquez.   

Abstract

Diabetes mellitus (DM) is complicated by vascular and neurological events. Antiphospholipid (aPL) antibodies have already been associated with many clinical conditions, including venous and arterial thrombosis, as well as recurrent fetal loss. However, a significant association between aPL antibodies and DM has not been widely reported yet. In the present study, we investigated the prevalence of aPL antibodies in diabetic patients. This study included 100 Chilean diabetic patients (67 of them with some complications and 33 without complications; 28 with Type 1 and 72 with Type 2 DM) and 100 healthy blood donor controls. Each sample was analyzed for IgG, IgM and IgA anticardiolipin (aCL), anti-beta(2) glycoprotein I (anti-beta(2)GPI), antiprothrombin (aPT) antibodies, and lupus anticoagulant (LA). Fourteen out of 100 (14%) diabetic patients presented some type of aPL antibodies. Four patients were positive for aCL antibodies, two for anti-beta(2)GPI antibodies, and nine for aPT antibodies. All patients were LA negative. The incidence of different isotypes was similar in each of the aPL antibodies studied, and their activities were low. No significant correlation was observed between aPL antibodies and vascular complications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15866057     DOI: 10.1016/j.jdiacomp.2004.09.004

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  2 in total

1.  Anticardiolipin antibodies in patients with type 2 diabetes mellitus.

Authors:  José María Calvo-Romero; Esther María Lima-Rodríguez
Journal:  Clin Med Res       Date:  2009-02-26

2.  Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?

Authors:  Giulia Ferrannini; Elisabet Svenungsson; Barbro Kjellström; Kerstin Elvin; Giorgia Grosso; Per Näsman; Lars Rydén; Anna Norhammar
Journal:  Diab Vasc Dis Res       Date:  2020 Mar-Apr       Impact factor: 3.291

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.